Concerta for attention deficit hyperactivity disorder treatment in children, adolescents, and adults

Concerta is a central nervous system stimulant medication formulated as extended-release tablets. It is approved for treating attention deficit hyperactivity disorder (ADHD) in children aged 6 years and older, adolescents, and adults up to 65 years old. It is designed to be taken once daily, providing sustained symptom control throughout the day.

Concerta is indicated for the treatment of ADHD in:

• Children aged 6 years and older
• Adolescents
• Adults up to 65 years of age

It is used as part of a comprehensive treatment program that may include psychological, educational, and social interventions. The diagnosis of ADHD must be based on DSM-IV criteria, including a consistent pattern of inattentive and/or hyperactive-impulsive symptoms causing impairment in two or more settings and starting before age 7.

methylphenidate hydrochloride

Concerta contains methylphenidate hydrochloride, a central nervous system stimulant that affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. The extended-release formulation allows gradual release of methylphenidate, providing consistent symptom management over the day with a single morning dose.

Concerta is administered orally once daily in the morning and must be swallowed whole with liquids; it should not be chewed, divided, or crushed. It can be taken with or without food.

Starting Dose

• Children (6–12 years): 18 mg once daily
• Adolescents (13–17 years): 18 mg once daily
• Adults (18–65 years): 18 or 36 mg once daily

Dose Titration

• Doses may be increased by 18 mg increments at weekly intervals
• Maximum doses: 54 mg/day in children, 72 mg/day in adolescents and adults
• A 27-mg tablet strength is available for dosing between 18 mg and 36 mg

Conversion from other methylphenidate regimens

Maintenance and Long-Term Use

The duration of treatment is individualized. Long-term (beyond 7 weeks) use has not been systematically studied in controlled trials, so periodic re-evaluation of treatment benefit and trials off medication are recommended to assess continued need.

Dose Reduction and Discontinuation

• If symptoms worsen or adverse events occur, reduce dose or discontinue
• If no improvement after one month at an appropriate dose, discontinue treatment

• Known hypersensitivity to methylphenidate or any component of the product
• Marked anxiety, tension, or agitation
• Glaucoma
• Motor tics or family history/diagnosis of Tourette's syndrome
• Concomitant or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)

Serious Cardiovascular Risks

• Sudden death has been reported in children, adolescents, and adults with serious structural heart abnormalities or other heart problems taking stimulants at usual doses.
• Stimulants should generally not be used in patients with known serious cardiac structural abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, or other serious heart issues.
• Monitor blood pressure and heart rate regularly, as stimulants can modestly increase both.

Psychiatric Adverse Events

• Can cause new or worsening psychotic or manic symptoms, including hallucinations or delusions, particularly in those without prior history.
• Patients with bipolar disorder should be carefully evaluated prior to initiation due to risk of triggering manic episodes.
• Monitor for aggressive behavior and worsening psychiatric symptoms.

Seizures

• May lower seizure threshold; discontinue if seizures occur.

Growth Suppression in Children

• Long-term use may temporarily slow growth in height and weight; monitor growth regularly and consider treatment interruption if growth is inadequate.

Visual Disturbances

• Difficulties with accommodation and blurred vision have been reported.

Gastrointestinal Concerns

• Concerta tablets are nondeformable and should not be used in patients with severe gastrointestinal narrowing or motility disorders.

Drug Dependence

• Use with caution in patients with a history of drug dependence or alcoholism.
• Chronic abuse can lead to tolerance, psychological dependence, and abnormal behavior.
• Withdrawal can unmask underlying psychiatric symptoms requiring follow-up.

Common side effects are not explicitly listed in the provided evidence.

Serious side effects include:

• Psychotic or manic symptoms
• Cardiovascular events such as sudden death, stroke, or myocardial infarction in patients with underlying heart disease
• Seizures
• Hypersensitivity reactions including angioedema and anaphylaxis

Concerta is contraindicated during treatment with monoamine oxidase (MAO) inhibitors and within 14 days of discontinuing an MAO inhibitor due to the risk of hypertensive crisis.